Guggenheim Capital LLC Supernus Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$27.11 - $35.17 $135,685 - $176,025	5,005 Added 55.03%	14,100 $480,000
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $206,638 - $269,939	9,095 New	9,095 $263,000
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $411,083 - $532,305	13,744 New	13,744 $413,000
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $695,172 - $846,996	22,360 New	22,360 $797,000
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $841,158 - $1.14 Million	33,208 New	33,208 $960,000
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $204,024 - $264,760	-7,737 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $130,788 - $174,402	-5,556 Reduced 41.8%	7,737 $206,000
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $33,533 - $41,653	-1,255 Reduced 8.63%	13,293 $409,000
Q1 2021 May 13, 2021	SELL	$24.15 - $31.45 $551,730 - $718,506	-22,846 Reduced 61.1%	14,548 $381,000
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $408,108 - $595,101	23,057 Added 160.82%	37,394 $941,000
Q3 2020 Nov 13, 2020	SELL	$20.2 - $25.05 $85,910 - $106,537	-4,253 Reduced 22.88%	14,337 $299,000
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $17,773 - $25,885	-1,040 Reduced 5.3%	18,590 $442,000
Q1 2020 Jun 02, 2020	SELL	$14.45 - $24.69 $23,842 - $40,738	-1,650 Reduced 7.75%	19,630 $354,000
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $114,298 - $167,060	-5,735 Reduced 21.23%	21,280 $505,000
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $1.52 Million - $1.99 Million	-59,566 Reduced 68.8%	27,015 $743,000
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $127,090 - $164,886	4,242 Added 5.15%	86,581 $2.87 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $293,914 - $376,608	8,969 Added 12.22%	82,339 $2.89 Million
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $422,816 - $678,782	-13,710 Reduced 15.74%	73,370 $2.44 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $278,446 - $368,762	6,521 Added 8.09%	87,080 $4.38 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $845,838 - $1.15 Million	-19,180 Reduced 19.23%	80,559 $4.82 Million
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $316,443 - $399,494	-8,518 Reduced 7.87%	99,739 $4.57 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $502,028 - $587,539	-13,792 Reduced 11.3%	108,257 $4.31 Million
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $4.49 Million - $6.06 Million	122,049	122,049 $4.88 Million

Others Institutions Holding SUPN

# of Institutions

283

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$401 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$236 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$196 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$111 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$101 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account